- Details
- Zachary Klaassen interviews Laurence Albiges about the CaboPoint Phase II Trial. Dr. Albiges discusses the evolving landscape of second-line treatment for clear cell renal cell carcinoma (RCC) after first-line immunotherapy combinations. The CaboPoint study evaluates cabozantinib as a pure second-line treatment in patients who have failed either nivolumab-ipilimumab or an IO-TKI strategy. Results...
|
- Details
- Chiara Ciccarese discusses the TACITO-II trial results, evaluating fecal microbiota transplantation (FMT) in patients receiving pembrolizumab plus axitinib for metastatic renal cell carcinoma. The phase II randomized study shows promising results, with FMT increasing the one-year progression-free survival rate from 35% to 66.7%. Dr. Ciccarese highlights the trial's novelty in demonstrating the tra...
|
- Details
- Eric Jonasch discusses data on NKT2152, a novel HIF-2 alpha inhibitor for clear cell renal cell carcinoma. The phase 1/2 study shows promising results in heavily pre-treated patients, with objective response rates around 25% and median progression-free survival of 7.4 months. Dr. Jonasch highlights the drug's efficacy across risk groups and its favorable safety profile, with anemia as the most com...
|
- Details
- Toni Choueiri discusses the TiNivo-2 trial results, comparing tivozanib-nivolumab combination to tivozanib monotherapy in advanced clear cell renal cell carcinoma. The study, involving 343 patients, shows no benefit in rechallenging with nivolumab after prior immunotherapy. Tivozanib monotherapy demonstrates efficacy, particularly in patients progressing directly from immunotherapy, with a progres...
|
- Details
- Lymphocytes are closely linked to mechanisms of action of immuno-oncology (IO) agents. We aimed to assess the prognostic significance of absolute lymphocyte count (ALC) in patients with metastatic renal cell carcinoma (mRCC). Biographies: Kosuke Takemura, MD, PhD, MPH, Staff Urologist, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan Related Content: Prognostic Sign...
|
- Details
- Pedro Barata interviews Yousef Zakharia about a phase 1/2 trial combining durvalumab and guadecitabine in metastatic kidney cancer. The study, conducted through the Big Ten Cancer Consortium, explores the potential synergy between hypomethylating agents and checkpoint inhibitors. Dr. Zakharia discusses the trial design, results, and biomarker findings. While the primary endpoint of objective respo...
|
- Details
- Alicia Morgans hosts Shankar Siva who sheds light on the innovative use of Stereotactic Ablative Body Radiotherapy (SBRT/SABR) for treating oligometastatic kidney cancer. Dr. Siva outlines the three clinical scenarios where SABR is employed: de novo oligometastatic disease, oligoprogressive disease during systemic therapy, and in certain de novo metastatic settings. He emphasizes the effectiveness...
|
- Details
- Dan George discusses the CheckMate-67T study with Saby George, a phase three trial comparing intravenous and subcutaneous administration of nivolumab in treatment-refractory kidney cancer patients. Conducted across 73 centers in 17 countries, this trial aimed to assess if subcutaneous nivolumab could match the systemic effects of its IV counterpart. Meeting its co-primary pharmacokinetic endpoints...
|
- Details
- Pedro Barata and Nizar Tannir delve into the eight-year results of the CheckMate-214 trial, showcasing the sustained efficacy of ipilimumab and nivolumab (ipi/nivo) in advanced renal cell carcinoma (RCC). Dr. Tannir highlights the treatment's enduring hazard ratio and significant mortality risk reduction, emphasizing the notable longevity and durability of patient responses. Their conversation nav...
|
- Details
- Dimitrios Makrakis presents a significant meta-analysis exploring the role of cytoreductive nephrectomy in patients undergoing immune checkpoint inhibition for metastatic renal cell carcinoma. This study, a substantial effort involving 2,319 patients, sought to address the gap in understanding post-CARMENA, focusing on outcomes in the era of immune checkpoint inhibitors. The analysis, utilizing in...
|
